Velan Capital Investment Management LP Sells 1,951,514 Shares of InspireMD, Inc. $NSPR

Velan Capital Investment Management LP cut its position in shares of InspireMD, Inc. (NYSE:NSPR) by 92.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 148,138 shares of the company’s stock after selling 1,951,514 shares during the quarter. Velan Capital Investment Management LP’s holdings in InspireMD were worth $104,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Nantahala Capital Management LLC purchased a new stake in InspireMD in the 2nd quarter valued at about $2,363,876. Parkman Healthcare Partners LLC bought a new position in shares of InspireMD during the 2nd quarter worth approximately $1,692,000. Orbimed Advisors LLC boosted its stake in shares of InspireMD by 46.9% in the 4th quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock worth $5,577,000 after buying an additional 1,000,000 shares during the last quarter. Soleus Capital Management L.P. boosted its stake in shares of InspireMD by 99.5% in the 2nd quarter. Soleus Capital Management L.P. now owns 1,886,207 shares of the company’s stock worth $4,282,000 after buying an additional 940,831 shares during the last quarter. Finally, Ingalls & Snyder LLC boosted its stake in shares of InspireMD by 70.8% in the 4th quarter. Ingalls & Snyder LLC now owns 384,300 shares of the company’s stock worth $684,000 after buying an additional 159,298 shares during the last quarter. 44.78% of the stock is owned by institutional investors.

InspireMD Stock Down 7.5%

NSPR stock opened at $0.84 on Thursday. The firm has a market cap of $39.06 million, a PE ratio of -1.12 and a beta of 0.82. The business has a 50 day moving average of $0.77 and a 200-day moving average of $1.12. InspireMD, Inc. has a 12-month low of $0.63 and a 12-month high of $2.56.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.